Effects and feedback of dupilumab/dalbitux in the treatment of skin diseases

The effectiveness of dupilumab in the treatment of skin diseases, especially in the treatment of moderate to severe atopic dermatitis (eczema), has been verified by a large amount of clinical data. Atopic dermatitis is a chronic skin disease caused by an overreaction of the immune system, usually characterized by symptoms such as dry skin, redness, and itching. For many patients, traditional treatments, such as topical corticosteroids, are ineffective at controlling symptoms or cannot be used long-term due to side effects. Therefore, dupilumab, as a new type of immunomodulatory therapeutic drug, has become an important breakthrough in this field.

In the treatment of atopic dermatitis, dupilumab can reduce the inflammatory response triggered by the immune system by inhibiting the effects of IL-4 and IL-13, two key cytokines, thereby alleviating skin symptoms. Clinical studies have shown that patients treated with dupilumab experienced significant improvements in symptoms such as skin redness, itching, and dryness. In the first few weeks of treatment, the patient's skin condition usually shows a significant improvement, especially in relieving allergic reactions and improving skin repair, dupilumab has a more prominent effect.

Not only that, dupilumab can also be used in children and adult patients, and has a wide range of applications. Patients 6 months and older can receive this treatment. For those patients whose disease cannot be effectively controlled by topical drugs, dupilumab provides a new treatment option. Feedback on the treatment has been generally positive, with many patients reporting significant relief of symptoms and improvement in quality of life.

In addition, dupilumab is not only effective in the treatment of atopic dermatitis, but also shows good therapeutic effects on other immune skin diseases, such as prurigo nodularis. In patients 12 years of age and older, dupilumab may also be used to treat chronic spontaneous urticaria, especially in patients who have not experienced effective relief with H1 antihistamines.

Reference materials：https://www.drugs.com/dupixent.html